Eliem Therapeutics, Inc.
Net BuyingELYM·US·🇺🇸 US
68%buys·32%sells
293 transactions$635.0MTotal buys·44 buys
$3.5MTotal sells·21 sells
3030 insiders
Last: Dec 12, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Dec 12, 25 | RA Capital Nexus Fund II, L.P. | Buy | $290K | |
| Dec 12, 25 | RA Capital Biotech Fund LP | Buy | $290K | |
| Dec 12, 25 | RA Capital Nexus Fund, L.P. | Buy | $290K | |
| Dec 12, 25 | RA CAPITAL MANAGEMENT, LLC | Buy | $290K | |
| Dec 12, 25 | RA Capital Nexus Fund III, L.P. | Buy | $290K | |
| Dec 12, 25 | Shah Rajeev M. | Buy | $290K | |
| Dec 12, 25 | Kolchinsky Peter | Buy | $290K | |
| Dec 11, 25 | RA Capital Nexus Fund II, L.P. | Grant | - | |
| Dec 11, 25 | RA Capital Biotech Fund LP | Grant | - | |
| Dec 11, 25 | RA Capital Nexus Fund, L.P. | Grant | - |
Eliem Therapeutics, Inc. is seeing coordinated insider buying. 7 insiders purchased shares in the last 30 days, with total buy volume of $2.0M. Overall insider sentiment is bullish (68% purchases).
Eliem Therapeutics, Inc. (ELYM) has recorded 293 insider operations, including 44 open-market purchases ($635.0M), 21 sales ($3.5M) and 228 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bullish (68% purchases).
Eliem Therapeutics, Inc. shows moderate insider activity with 7 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are Azelby Robert (CEO), Brennan Aoife (CEO) & ALTSCHULLER Susan (CFO), with respectively 73, 56, 17 transactions.
Across all 293 recorded transactions, the breakdown by type is: exercise (115, 39%), grant (106, 36%), buys (44, 15%), sells (21, 7%), disposition (7, 2%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Eliem Therapeutics, Inc. has recorded 293 insider operations in total, including 44 open-market purchases ($635.0M), 21 sales ($3.5M) and 228 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on December 12, 2025.
Insiders at Eliem Therapeutics, Inc. are currently net buyers, with 68% purchases and 32% sales across all reported transactions. Total buy volume is $635.0M versus $3.5M in sales, indicating a bullish insider sentiment.
InsiderLens tracks 30 insiders at Eliem Therapeutics, Inc. (ELYM). Azelby Robert (CEO, 73 tx), Brennan Aoife (CEO, 56 tx), ALTSCHULLER Susan (CFO, 17 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for ELYM is bullish, based on a 68% buy ratio across 65 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Eliem Therapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.